Nonsense mutations cause several genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, β-thalassemia, and Shwachman–Diamond syndrome. These mutations induce the formation of a premature termination codon (PTC) inside the mRNA sequence, resulting in the synthesis of truncated polypeptides. Nonsense suppression therapy mediated by translational readthrough-inducing drugs (TRIDs) is a promising approach to correct these genetic defects. TRIDs generate a ribosome miscoding of the PTC named “translational readthrough” and restore the synthesis of full-length and potentially functional proteins. The new oxadiazole-core TRIDs NV848, NV914, and NV930 (NV) showed translational readthrough activity in nonsense-related in vitro systems. In this work, the possible off-target effect of NV molecules on natural termination codons (NTCs) was investigated. Two different in vitro approaches were used to assess if the NV molecule treatment induces NTC readthrough: (1) a study of the translational-induced p53 molecular weight and functionality; (2) the evaluation of two housekeeping proteins’ (Cys-C and β2M) molecular weights. Our results showed that the treatment with NV848, NV914, or NV930 did not induce any translation alterations in both experimental systems. The data suggested that NV molecules have a specific action for the PTCs and an undetectable effect on the NTCs.
Nonsense mutations, often resulting from single-nucleotide substitutions, produce mRNA harboring a premature termination codon (PTC), which causes the premature termination of protein synthesis. This produces truncated and non-functional proteins, which cause different genetic diseases, including cystic fibrosis (CF). This work aims to investigate the ability of NV848 (N-(5-methyl-1,2,4-oxadiazol-3-yl)acetamide), a translational readthrough-inducing drug (TRID), to rescue CF transmembrane conductance regulator (CFTR) protein expression in a murine model characterized by the G542X nonsense mutation in the CFTR gene. In vitro experiments assessed the drug's stability in human hepatic metabolism, and in vivo investigations on wild-type mice allowed us to clarify the distribution of the drug to the target organs. Moreover, its efficacy in recovering the CFTR protein after chronic treatment was assessed in G542X homozygous mice. Our results provide valuable insights into the biodistribution and therapeutic attributes of NV848, representing a promising therapeutic tool for enhanced clinical outcomes in individuals affected by CF with nonsense mutations.
3 April 2025 in European Journal of Organic Chemistry
The growing interest toward biopolymers application in amphiphilic conditions prompts one to explore the preparation of fluorinated cellulosic materials. Cellulose (CE) and carboxymethylcellulose (CMC) are functionalized with highly fluorinated pendants, through a nucleophilic aromatic substitution on 3‐pentadecafluoroheptyl‐5‐pentafluorophenyl‐1,2,4‐oxadiazole (FOX) leading to the corresponding fluorinated biopolymers CE‐FOX and CMC‐FOX. Structural and thermal stability confirm covalent attachment of the fluorinated moiety onto the cellulosic skeleton and highlighted an interesting 2D texture of the CMC‐FOX material. Hybrid and amphiphilic features of CE‐FOX and CMC‐FOX, are confirmed by water and oil contact angle measurements. Applications as adsorbent material for organic contaminants from an aqueous solution are tested by previously incorporating the functional biopolymer into sodium alginate (SA) hydrogel beads. Rhodamine B (RhB) is used as a model wastewater pollutant. Fluoro‐functionalization led to a three‐ to eightfold increase in the dye‐removal efficiency of the SA‐incorporated biopolymer with respect to the corresponding non‐fluorinated material (from 11% to 48% for SA/CE vs SA/CE‐FOX beads and from 11% to 94% for SA/CMC vs SA/CMC‐FOX beads). Recyclability tests show good residual performance of SA/CMC‐FOX beads after seven desorption/reuse cycles opening the way to more sustainable adsorbing processes for the removal of emerging pollutants from contaminated water.
15 July 2025 in Journal of Environmental Chemical Engineering
Nonsense mutations cause several genetic diseases such as Cystic fibrosis, Duchenne muscular dystrophy, β-thalassemia, and Shwachman-Diamond syndrome. These mutations induce the formation of a premature termination codon (PTC) inside the mRNA sequence that leads to the aberrant translation, resulting in the synthesis of truncated polypeptides. Nonsense suppression therapy mediated by translational readthrough-inducing drugs (TRIDs) is a promising approach to correct these genetic defects. TRIDs generate a ribosome miscoding of the PTC named “translational readthrough” and restore the synthesis of full-length and potentially functional protein. The new oxadiazole-core TRIDs NV848, NV914, and NV930 showed translational readthrough activity in nonsense-related in vitro systems. In this work, the possible off-target effect of NV molecules on natural termination codons (NTCs) was investigated. Two different in vitro approaches were used to assess if the NV molecules treatment induce NTCs readthrough: 1) A study of translational induced p53 molecular weight and functionality; 2) the evaluation of two housekeeping proteins (Cys-C and β2M) molecular weights. Our results showed that the treatment with NV848, NV914, or NV930 do not induce any translation alterations in both experimental systems. Data suggested that NV molecules have a specific action for the PTCs and an undetectable effect on the NTCs.